Ublituximab
Ublituximab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myasthenia Gravis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
15 项
全球在招研究
5 项
已进入 III/IV 期
10 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- TG Therapeutics, Inc.
- Imperial College London
- National Institute of Allergy and Infectious Diseases (NIAID)
- Neurology Center of New England P.C.
- Georgia State University
- Northwestern University
- University of Maryland, Baltimore
- Johns Hopkins University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Poland、Slovakia、Puerto Rico、英国、Bosnia and Herzegovina、Georgia、North Macedonia、Serbia、Ukraine
正在招募患者的 Ublituximab 研究
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
II 期 / III 期招募中美国PolandSlovakiaNCT07220252A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
不适用招募中美国NCT06433765A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
不适用招募中美国Puerto Rico英国NCT06433752Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
II 期招募中美国NCT07680946REAL-MS: Observational Database Study of AHSCT and MS Therapies
不适用招募中英国NCT07899502Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
II 期招募中美国NCT07103746A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
II 期招募中美国NCT07673744A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
不适用招募中美国NCT06681623Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
III 期招募中美国PolandNCT05877963Effects of Ublituximab on Motor Functions in Multiple Sclerosis
早期 I 期招募中美国NCT06629428A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
II 期招募中Bosnia and HerzegovinaGeorgiaNorth MacedoniaPolandNCT07503873Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
IV 期招募中美国NCT07225361Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
不适用招募中美国NCT06864936Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
IV 期招募中美国NCT07389590Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
III 期招募中美国NCT04047628
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。